Top Industry Leaders in the Acute Agitation Aggression Treatment Market
Latest Acute agitation aggression treatment Companies Update
Eli Lilly and Company (US) Received FDA approval for Lumateperone (Caplyta®) in July 2023 for the treatment of agitation associated with schizophrenia in adults. This new medication offers another option for addressing the specific needs of this population.
Lundbeck (Denmark) Announced positive Phase 3 trial results for Lu AF56950A in the treatment of agitation associated with dementia in October 2023. This investigational medication may provide a novel non-benzodiazepine option for this challenging condition.
Alkermes (US) Partnered with Otsuka Holdings Co., Ltd. (Japan) in June 2023 to develop and commercialize ALKS 5461 for the treatment of agitation associated with Alzheimer's disease and other neurodegenerative disorders. This collaboration brings together expertise for potential future advancements.
Brainsway (Israel) Expanded its non-invasive Deep Transcranial Magnetic Stimulation (dTMS) therapy offerings with the FDA clearance of the Deep TMS System for the treatment of major depressive disorder with anxious distress in September 2023. This technology may find application in managing agitation associated with specific mental health conditions.
Bionest LCC (US) Developed the Sedasys® Patient Management System, a non-invasive vagus nerve stimulation device for managing anxiety and potentially reducing the need for antipsychotics in some agitation episodes. This technology offers a unique approach to treatment.
List of Acute Agitation Aggression Treatment Key Companies in the Market
- Eli Lilly and Company (US)
- Pfizer Inc (US)
- GlaxoSmithKline plc (UK)
- Teva Pharmaceutical Industries Ltd (Israel)
- Otsuka Holdings Co., Ltd (Japan)
- VIATRIS INC (US)
- Johnson & Johnson Services, Inc (US)
- Novartis AG (Switzerland)
- Lundbeck A/S (Denmark)
- Amneal Pharmaceuticals LLC (US)